Abstract: The present invention pertains to a vaccine comprising an immunologically effective amount of an IgM protease antigen of Streptococcus suis, for use in a method for protecting pigs against a pathogenic infection with Streptococcus suis by administering the vaccine only once, wherein the vaccine comprises at most 120 ?g per dose of the antigen.

Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting pigs against an infection with Streptococcus suis of serotype 2 and against an infection with Streptococcus suis of serotype 14.

Abstract: The present invention pertains to a vaccine comprising (a) an immunologically effective amount of a Streptococcus suis IgM protease antigen, (b) an immunologically effective amount of an Escherichia coli fibmrial antigen, and (c) an immunologically effective amount of a Clostridium toxoid, and also pertains to use of the vaccine in a method for protecting pigs against a pathogenic infection with Streptococcus suis, Escherichia coli and Clostridium.

Abstract: The invention pertains to a serine protease antigen which induces antibodies against a protein having at least 69% sequence identity with the Heamophilus parasuis protein according to SEQ ID No: 1, for use in a prophylactic method to protect a pig against an infection with Haemophilus parasuis by administering a vaccine to the pig, wherein the vaccine comprises the serine protease antigen. The invention also pertains to a vaccine, a method to manufacture such a vaccine and a method to protect a pig against H. parasuis.

Abstract: The invention pertains to a protein having at least 69% sequence identity with the protein according to SEQ ID No: 1 or an immunogenic fragment of this protein, for use in a prophylactic method to protect a pig against an infection with Haemophilus parasuis serotype 4 and an infection with Haemophilus parasuis serotype 5, by administering a vaccine to the pig, the vaccine comprising the protein or the immunogenic fragment thereof as an antigen. The invention also pertains to a vaccine, a method to manufacture such a vaccine and a method to protect a pig against H. parasuis.

Abstract: The invention pertains to a protein having at least 69% sequence identity with the protein according to SEQ ID No: 1 or an immunogenic fragment of this protein, for use in a prophylactic method to protect a pig against an infection with Haemophilus parasuis by administering a vaccine to the pig, the vaccine comprising the protein or the immunogenic fragment thereof as an antigen. The invention also pertains to a vaccine, a method to manufacture such a vaccine and a method to protect a pig against H. parasuis.

Abstract: The present invention pertains to a vaccine comprising an immunologically effective amount of an IgM protease antigen of Streptococcus suis, for use in a method for protecting pigs against a pathogenic infection with Streptococcus suis by administering the vaccine only once, wherein the vaccine comprises at most 120 ?g per dose of the antigen.

Abstract: The present invention pertains to a combination of a first vaccine comprising non-replicating immunogen of porcine circo virus type 2 (PCV2) and non-replicating immunogen of Mycoplasma hyopneumoniae, and a second vaccine comprising live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating an animal against an infection with porcine circovirus type 2, an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus, by associated non-mixed administration of the first vaccine and the second vaccine to the animal. The invention also pertains to a kit-of-parts comprising the first and second vaccine and to a method of protecting an animal against such infections using these vaccines.

Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting a pig against Streptococcus suis, characterised in that the IgM protease antigen is a protein according to SEQ ID NO:1.

Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting pigs against an infection with Streptococcus suis of serotype 2 and against an infection with Streptococcus suis of serotype 14.

Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting piglets having maternally derived anti-Streptococcus suis antibodies against Streptococcus suis, by administering the vaccine to the piglets at an age of at most 28 days, preferably before the piglets are weaned.

Abstract: The invention pertains to a vaccine comprising in combination non-replicating immunogens of Erysipelothrix rhusiopathiae, porcine parvo virus, Leptospira interrogans and live attenuated PRRS virus, and a pharmaceutically acceptable carrier, for use in a method for prophylactic treatment of a swine against an infection with Erysipelothrix rhusiopathiae, porcine parvo virus, Leptospira interrogans and PRRS virus, wherein the vaccine is administered in a single dose with regard to the treatment against an infection with PRRS virus.

Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting pigs against an infection with Streptococcus suis of serotype 2 and against an infection with Streptococcus suis of serotype 9.

Abstract: The present invention pertains to a vaccine comprising (a) an immunologically effective amount of a Streptococcus suis IgM protease antigen, (b) an immunologically effective amount of an Escherichiacoli fibmrial antigen, and (c) an immunologically effective amount of a Clostridium toxoid, and also pertains to use of the vaccine in a method for protecting pigs against a pathogenic infection with Streptococcus suis, Escherichia coli and Clostridium.

Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting pigs against an infection with Streptococcus suis of serotype 2 and against an infection with Streptococcus suis of serotype 9.

Abstract: The invention pertains to a vaccine comprising in combination non-replicating immunogens of Erysipelothrix rhusiopathiae, porcine parvo virus, Leptospira interrogans and live attenuated PRRS virus, and a pharmaceutically acceptable carrier, for use in a method for prophylactic treatment of a swine against an infection with Erysipelothrix rhusiopathiae, porcine parvo virus, Leptospira interrogans and PRRS virus, wherein the vaccine is administered in a single dose with regard to the treatment against an infection with PRRS virus.

Abstract: The present invention pertains to a vaccine comprising non live Lawsonia intracellularis antigen and a pharmaceutically acceptable carrier for use in a method to reduce in a pig the negative impact on average daily weight gain (ADWG) associated with subclinical infection with Lawsonia intracellularis, by systemic administration of the vaccine to the pig.

Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method wherein a female pig is vaccinated in order to protect a piglet against Streptococcus suis through the intake of colostrum of the vaccinated female pig.

Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting piglets having maternally derived anti-Streptococcus suis antibodies against Streptococcus suis, by administering the vaccine to the piglets at an age of at most 28 days, preferably before the piglets are weaned.

Abstract: The present invention pertains to a combination of a first vaccine comprising non-replicating immunogen of porcine circo virus type 2 (PCV2) and non-replicating immunogen of Mycoplasma hyopneumoniae, and a second vaccine comprising live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating an animal against an infection with porcine circovirus type 2, an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus, by associated non-mixed administration of the first vaccine and the second vaccine to the animal. The invention also pertains to a kit-of-parts comprising the first and second vaccine and to a method of protecting an animal against such infections using these vaccines.